Plain-English translation of NCT03321045 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new imaging technique using a radioactive tracer called 89Zr-trastuzumab combined with PET/MRI scanning. The goal is to see whether this scan can identify which patients with HER2-positive breast cancer are likely to benefit from targeted therapy before they start treatment. By taking pictures of how the medication attaches to cancer cells, doctors hope to predict who will respond well to this type of therapy.
Currently, doctors have limited ways to predict which patients will respond to targeted HER2 therapy before starting treatment. This medication is already used to treat some breast cancers, but not everyone benefits equally. This study could help doctors personalize treatment decisions and avoid giving ineffective therapy to patients who won't benefit.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive an injection of the radioactive tracer medication intravenously (through your arm). About 5 to 6 days later, you will come back for a PET/MRI imaging scan, which takes pictures of how the medication has attached to your cancer cells. The scan helps doctors see whether this new imaging approach can predict how well you'll respond to your targeted therapy.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States